

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Imipenem / Cilastatin / Relebactam Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.5	14.04.2025	68822-00033	Date of first issue: 27.02.2015

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Imipenem / Cilastatin / Relebactam Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Pharmaceutical

Recommended restrictions on use : Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD
Innishannon
County Cork - Ireland

Telephone : 353 214329300

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Eye irritation, Category 2	H319: Causes serious eye irritation.
Respiratory sensitisation, Category 1	H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled.
Reproductive toxicity, Category 2	H361d: Suspected of damaging the unborn child.
Specific target organ toxicity - repeated exposure, Category 2	H373: May cause damage to organs through prolonged or repeated exposure.
Short-term (acute) aquatic hazard, Category 1	H400: Very toxic to aquatic life.
Long-term (chronic) aquatic hazard, Category 1	H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Imipenem / Cilastatin / Relebactam Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.5	14.04.2025	68822-00033	Date of first issue: 27.02.2015

Hazard pictograms	:	
Signal word	:	Danger
Hazard statements	:	H319 H334 H361d H373 H410 Causes serious eye irritation. May cause allergy or asthma symptoms or breathing difficulties if inhaled. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure. Very toxic to aquatic life with long lasting effects.
Precautionary statements	:	Prevention: P260 P273 P280 Do not breathe dust. Avoid release to the environment. Wear protective gloves/ protective clothing/ eye protection/ face protection. Response: P304 + P340 P342 + P311 P391 IF INHALED: Remove person to fresh air and keep comfortable for breathing. If experiencing respiratory symptoms: Call a POISON CENTER/ doctor. Collect spillage.

Hazardous components which must be listed on the label:

Imipenem
Relebactam

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Imipenem / Cilastatin / Relebactam Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.5	14.04.2025	68822-00033	Date of first issue: 27.02.2015

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Cilastatin	81129-83-1 279-694-4	Eye Irrit. 2; H319	>= 30 - < 50
Imipenem	74431-23-5	Resp. Sens. 1A; H334 Repr. 2; H361d Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 100 M-Factor (Chronic aquatic toxicity): 10	>= 30 - < 50
Relebactam	1174020-13-3	STOT RE 2; H373 (Kidney)	>= 10 - < 20

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

- | | |
|----------------------------|---|
| General advice | : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice. |
| Protection of first-aiders | : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| If inhaled | : If inhaled, remove to fresh air.
If not breathing, give artificial respiration.
If breathing is difficult, give oxygen.
Get medical attention. |
| In case of skin contact | : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes. |

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Imipenem / Cilastatin / Relebactam Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.5	14.04.2025	68822-00033	Date of first issue: 27.02.2015

		Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks	:	Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome). Contact with dust can cause mechanical irritation or drying of the skin. Causes serious eye irritation. May cause allergy or asthma symptoms or breathing difficulties if inhaled. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure.
-------	---	---

4.3 Indication of any immediate medical attention and special treatment needed

Treatment	:	Treat symptomatically and supportively.
-----------	---	---

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	:	None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion prod-	:	Carbon oxides

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Imipenem / Cilastatin / Relebactam Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.5	14.04.2025	68822-00033	Date of first issue: 27.02.2015

ucts

Metal oxides

5.3 Advice for firefighters

- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

- Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

- Methods for cleaning up : Surround spill with absorbents and place a damp covering over the area to minimise entry of the material into the air.
Add excess liquid to allow the material to enter into solution.
Soak up with inert absorbent material.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Imipenem / Cilastatin / Relebactam Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.5	14.04.2025	68822-00033	Date of first issue: 27.02.2015

SECTION 7: Handling and storage

7.1 Precautions for safe handling

- | | | |
|-------------------------|---|--|
| Technical measures | : | Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | : | Use only with adequate ventilation. |
| Advice on safe handling | : | Do not breathe dust.
Do not swallow.
Do not get in eyes.
Avoid prolonged or repeated contact with skin.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

7.2 Conditions for safe storage, including any incompatibilities

- | | | |
|---|---|---|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations. |
| Advice on common storage | : | Do not store with the following product types:
Strong oxidizing agents |

7.3 Specific end use(s)

- | | | |
|-----------------|---|-------------------|
| Specific use(s) | : | No data available |
|-----------------|---|-------------------|

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Imipenem / Cilastatin / Relebactam Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.5	14.04.2025	68822-00033	Date of first issue: 27.02.2015

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

dusts non-specific	4 mg/m ³ Value type (Form of exposure): OELV - 8 hrs (TWA) (Respirable dust) Basis: IE OEL
	10 mg/m ³ Value type (Form of exposure): OELV - 8 hrs (TWA) (inhalable dust) Basis: IE OEL

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Cilastatin	81129-83-1	TWA	5 mg/m ³ (OEB 1)	Internal
Imipenem	74431-23-5	TWA	3000 µg/m ³ (OEB 1)	Internal
Further information: RSEN, DSEN				
		Wipe limit	100 µg/100 cm ²	Internal
Relebactam	1174020-13-3	TWA	0.3 mg/m ³ (OEB 2)	Internal

8.2 Exposure controls

Engineering measures

Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Eye/face protection	: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection Material	: Chemical-resistant gloves
Skin and body protection	: Work uniform or laboratory coat.
Respiratory protection	: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143
Filter type	: Particulates type (P)

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Imipenem / Cilastatin / Relebactam Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.5	14.04.2025	68822-00033	Date of first issue: 27.02.2015

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	:	powder
Colour	:	White to light yellow
Odour	:	No data available
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
pH	:	No data available
Viscosity		
Viscosity, dynamic	:	No data available
Viscosity, kinematic	:	Not applicable
Solubility(ies)		
Water solubility	:	soluble
Partition coefficient: n-octanol/water	:	Not applicable
Vapour pressure	:	Not applicable

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Imipenem / Cilastatin / Relebactam Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.5	14.04.2025	68822-00033	Date of first issue: 27.02.2015

Relative density : No data available

Density : No data available

Relative vapour density : Not applicable

Particle characteristics
Particle size : No data available

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : Not applicable

Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Imipenem / Cilastatin / Relebactam Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.5	14.04.2025	68822-00033	Date of first issue: 27.02.2015

Acute toxicity

Not classified based on available information.

Components:

Cilastatin:

Acute oral toxicity	:	LD50 (Rat): 8,000 mg/kg
		LD50 (Mouse): 8,000 mg/kg

Imipenem:

Acute oral toxicity	:	LD50 (Mouse): 10,000 mg/kg
Acute toxicity (other routes of administration)	:	LD50 (Rat): > 2,000 mg/kg Application Route: Intravenous
		LD50 (Mouse): 1,500 mg/kg Application Route: Intravenous

Skin corrosion/irritation

Not classified based on available information.

Components:

Cilastatin:

Species	:	Rabbit
Result	:	No skin irritation

Relebactam:

Method	:	EpiDerm
Result	:	No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

Cilastatin:

Species	:	Rabbit
Result	:	Moderate eye irritation

Relebactam:

Method	:	Bovine cornea (BCOP)
Result	:	No eye irritation

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Imipenem / Cilastatin / Relebactam Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.5	14.04.2025	68822-00033	Date of first issue: 27.02.2015

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:

Cilastatin:

Exposure routes	: Skin contact
Remarks	: No data available

Exposure routes	: Inhalation
Remarks	: No data available

Imipenem:

Remarks	: May cause sensitisation of susceptible persons by inhalation of aerosol or dust.
---------	--

Exposure routes	: Skin contact
Remarks	: Not classified due to lack of data.

Relebactam:

Test Type	: Local lymph node assay (LLNA)
Exposure routes	: Dermal
Result	: Not a skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

Components:

Cilastatin:

Genotoxicity in vitro	: Test Type: Microbial mutagenesis assay (Ames test) Result: negative
-----------------------	--

Imipenem:

Genotoxicity in vitro	: Test Type: In vitro mammalian cell gene mutation test Test system: Chinese hamster lung cells Result: negative
-----------------------	--

Test Type: reverse mutation assay Result: negative

Test Type: unscheduled DNA synthesis assay Result: negative
--

Test Type: Chromosomal aberration

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Imipenem / Cilastatin / Relebactam Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.5	14.04.2025	68822-00033	Date of first issue: 27.02.2015

Result: negative

Test Type: sister chromatid exchange assay
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Species: Mouse
Application Route: Intravenous
Result: negative

Relebactam:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow
cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Intraperitoneal injection
Result: negative

Germ cell mutagenicity- Assessment : Weight of evidence does not support classification as a germ
cell mutagen.

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Cilastatin:

Effects on fertility : Test Type: Fertility/early embryonic development
Application Route: Intravenous
Fertility: LOAEL: 1,000
Symptoms: No adverse effects
Result: No effects on fertility and early embryonic development were detected.

Imipenem:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, male and female
Application Route: Intravenous
Fertility: LOAEL: 80 mg/kg body weight
Symptoms: No adverse effects, Reduced foetal weight
Result: No effects on fertility and early embryonic development were detected.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Imipenem / Cilastatin / Relebactam Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.5	14.04.2025	68822-00033	Date of first issue: 27.02.2015

Test Type: Fertility/early embryonic development
Species: Rat, male and female
Application Route: Subcutaneous
Fertility: LOAEL: 320 mg/kg body weight
Symptoms: No adverse effects, Reduced foetal weight
Result: No effects on fertility and early embryonic develop-
ment were detected.

Effects on foetal develop-
ment : Test Type: Development
Species: Monkey
Application Route: Intravenous
Developmental Toxicity: LOAEL: 100 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the off-
spring were detected., No teratogenic effects

Test Type: Development
Species: Rabbit
Application Route: Intravenous
Developmental Toxicity: NOAEL: 60 mg/kg body weight
Result: No teratogenic effects

Test Type: Development
Species: Rat
Application Route: Intravenous
Developmental Toxicity: NOAEL: 60 mg/kg body weight
Result: No teratogenic effects

Reproductive toxicity - As-
sessment : Some evidence of adverse effects on development, based on
animal experiments.

Relebactam:

Effects on fertility : Test Type: Pre-/postnatal development
Species: Rat
Application Route: Subcutaneous
Fertility: NOAEL: 450 mg/kg body weight

Effects on foetal develop-
ment : Test Type: Embryo-foetal development
Species: Rat
Application Route: Intraperitoneal injection
Embryo-foetal toxicity: NOAEL: 450 mg/kg body weight
Result: No effects on foetal development

Test Type: Embryo-foetal development
Species: Mouse
Application Route: Intraperitoneal injection
Embryo-foetal toxicity: NOAEL: 450 mg/kg body weight
Result: No effects on foetal development

Test Type: Development
Species: Rat

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Imipenem / Cilastatin / Relebactam Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.5	14.04.2025	68822-00033	Date of first issue: 27.02.2015

Application Route: Intravenous
Developmental Toxicity: NOAEL: $\geq$ 450 mg/kg body weight
Result: No effects on fertility and early embryonic development were detected.

Test Type: Development
Species: Rabbit
Application Route: Intravenous
Developmental Toxicity: NOAEL: 450 mg/kg body weight
Result: No effects on foetal development

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:

Relebactam:

Target Organs	: Kidney
Assessment	: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Cilastatin:

Species	: Rat
NOAEL	: $\geq$ 500 mg/kg
Application Route	: Intravenous
Exposure time	: 90 Days
Remarks	: No significant adverse effects were reported

Species	: Monkey
NOAEL	: $\geq$ 500 mg/kg
Application Route	: Intravenous
Exposure time	: 5 Weeks
Remarks	: No significant adverse effects were reported

Imipenem:

Species	: Monkey
NOAEL	: 60 mg/kg
LOAEL	: 150 mg/kg
Application Route	: Intravenous
Exposure time	: 6 Months
Target Organs	: Kidney

Species	: Monkey
NOAEL	: 120 mg/kg

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Imipenem / Cilastatin / Relebactam Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.5	14.04.2025	68822-00033	Date of first issue: 27.02.2015

Application Route : Subcutaneous
Exposure time : 6 Months
Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 180 mg/kg
Application Route : Intravenous
Exposure time : 6 Months
Remarks : No significant adverse effects were reported

Species : Rabbit
LOAEL : 150 mg/kg
Application Route : Intravenous
Target Organs : Kidney

Relebactam:

Species : Rat, female
NOAEL : 150 mg/kg
Application Route : Intravenous
Exposure time : 30 d

Species : Rat, male
NOAEL : 450 mg/kg
Application Route : Intravenous
Exposure time : 30 d

Species : Monkey
NOAEL : 25 mg/kg
Application Route : Intravenous
Exposure time : 30 d
Target Organs : Kidney

Species : Monkey
NOAEL : 37.5 mg/kg
Application Route : Intravenous
Exposure time : 30 d

Species : Monkey
NOAEL : 50 mg/kg
LOAEL : 150 mg/kg
Application Route : Intravenous
Exposure time : 3 Months
Target Organs : Kidney

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Not classified based on available information.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Imipenem / Cilastatin / Relebactam Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.5	14.04.2025	68822-00033	Date of first issue: 27.02.2015

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

Imipenem:

Inhalation : Symptoms: Nausea, Vomiting, Diarrhoea, Fever, hypotension, Dizziness, Drowsiness, Convulsions, pruritis, Rash
Remarks: May cause sensitisation of susceptible persons by inhalation of aerosol or dust.

Relebactam:

Skin contact : Symptoms: Pain, Discomfort, Diarrhoea, Abdominal pain, insomnia, Nausea, sore throat, Vertigo

SECTION 12: Ecological information

12.1 Toxicity

Components:

Cilastatin:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 111 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): > 99 mg/l
aquatic invertebrates
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic : EC50 (Anabaena flos-aquae): > 99 mg/l
plants
Exposure time: 72 h
Method: OECD Test Guideline 201

EC50 (Pseudokirchneriella subcapitata (green algae)): > 99 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae): 99 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 99 mg/l

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Imipenem / Cilastatin / Relebactam Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.5	14.04.2025	68822-00033	Date of first issue: 27.02.2015

	Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to microorganisms	: EC50 : > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
Toxicity to fish (Chronic toxicity)	: EC10: > 9.9 mg/l Exposure time: 32 d Species: Pimephales promelas (fathead minnow) Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: EC10: > 10 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211
Imipenem:	
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 78 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: EC50 (Anabaena flos-aquae (cyanobacterium)): 0.0046 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
	NOEC (Anabaena flos-aquae (cyanobacterium)): 0.002 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
	EC50 (Pseudokirchneriella subcapitata (green algae)): > 74 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
	NOEC (Pseudokirchneriella subcapitata (green algae)): 74 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
M-Factor (Acute aquatic toxicity)	: 100
Toxicity to microorganisms	: EC50 : > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
Toxicity to fish (Chronic toxicity)	: NOEC: 9.4 mg/l Exposure time: 32 d

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Imipenem / Cilastatin / Relebactam Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.5	14.04.2025	68822-00033	Date of first issue: 27.02.2015

Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 11 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity) : 10

Relebactam:

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

EC50 (Americamysis): > 100 mg/l
Exposure time: 96 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 86 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 12 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

EC50 (Anabaena flos-aquae (cyanobacterium)): > 11 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae (cyanobacterium)): 11 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50 : > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC : 96.3 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity) : NOEC: 9.2 mg/l
Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

Toxicity to daphnia and other : NOEC: 2.7 mg/l

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Imipenem / Cilastatin / Relebactam Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.5	14.04.2025	68822-00033	Date of first issue: 27.02.2015

aquatic invertebrates (Chronic toxicity)

Exposure time: 21 d
Species: *Daphnia magna* (Water flea)
Method: OECD Test Guideline 211

12.2 Persistence and degradability

Components:

Cilastatin:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 27 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Imipenem:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 29 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Relebactam:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 11.3 %
Exposure time: 28 d
Method: OECD Test Guideline 314

12.3 Bioaccumulative potential

Components:

Cilastatin:

Partition coefficient: n-octanol/water : log Pow: -3.53

Imipenem:

Partition coefficient: n-octanol/water : log Pow: < -1

Relebactam:

Partition coefficient: n-octanol/water : log Pow: < -2

12.4 Mobility in soil

Components:

Cilastatin:

Distribution among environmental compartments : log Koc: 2.3

Relebactam:

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Imipenem / Cilastatin / Relebactam Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.5	14.04.2025	68822-00033	Date of first issue: 27.02.2015

Distribution among environ- : log Koc: 2.3
mental compartments

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product	: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN	: UN 3077
ADR	: UN 3077
RID	: UN 3077
IMDG	: UN 3077
IATA	: UN 3077

14.2 UN proper shipping name

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Imipenem / Cilastatin / Relebactam Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.5	14.04.2025	68822-00033	Date of first issue: 27.02.2015

ADN	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Imipenem)
ADR	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Imipenem)
RID	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Imipenem)
IMDG	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Imipenem)
IATA	:	Environmentally hazardous substance, solid, n.o.s. (Imipenem)

14.3 Transport hazard class(es)

	Class	Subsidiary risks
ADN	:	9
ADR	:	9
RID	:	9
IMDG	:	9
IATA	:	9

14.4 Packing group

ADN	
Packing group	: III
Classification Code	: M7
Hazard Identification Number	: 90
Labels	: 9
ADR	
Packing group	: III
Classification Code	: M7
Hazard Identification Number	: 90
Labels	: 9
Tunnel restriction code	: (-)
RID	
Packing group	: III
Classification Code	: M7
Hazard Identification Number	: 90
Labels	: 9
IMDG	
Packing group	: III
Labels	: 9

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Imipenem / Cilastatin / Relebactam Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.5	14.04.2025	68822-00033	Date of first issue: 27.02.2015

EmS Code	:	F-A, S-F
IATA (Cargo)		
Packing instruction (cargo aircraft)	:	956
Packing instruction (LQ)	:	Y956
Packing group	:	III
Labels	:	Miscellaneous
IATA (Passenger)		
Packing instruction (passenger aircraft)	:	956
Packing instruction (LQ)	:	Y956
Packing group	:	III
Labels	:	Miscellaneous

14.5 Environmental hazards

ADN	
Environmentally hazardous	: yes
ADR	
Environmentally hazardous	: yes
RID	
Environmentally hazardous	: yes
IMDG	
Marine pollutant	: yes
IATA (Passenger)	
Environmentally hazardous	: yes
IATA (Cargo)	
Environmentally hazardous	: yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks	:	Not applicable for product as supplied.
---------	---	---

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)	:	Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Not applicable

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Imipenem / Cilastatin / Relebactam Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.5	14.04.2025	68822-00033	Date of first issue: 27.02.2015

Regulation (EU) No 2024/590 on substances that de- plete the ozone layer	:	Not applicable
Regulation (EU) 2019/1021 on persistent organic pollu- tants (recast)	:	Not applicable
Regulation (EU) No 649/2012 of the European Parlia- ment and the Council concerning the export and import of dangerous chemicals	:	Not applicable
REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable
Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.		

E1	ENVIRONMENTAL HAZARDS	Quantity 1 100 t	Quantity 2 200 t
----	--------------------------	---------------------	---------------------

Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations,
where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national
regulations, where applicable.

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
-------------------	---	--

Full text of H-Statements

H319	:	Causes serious eye irritation.
H334	:	May cause allergy or asthma symptoms or breathing difficul- ties if inhaled.
H361d	:	Suspected of damaging the unborn child.
H373	:	May cause damage to organs through prolonged or repeated exposure.
H400	:	Very toxic to aquatic life.
H410	:	Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Aquatic Acute	:	Short-term (acute) aquatic hazard
Aquatic Chronic	:	Long-term (chronic) aquatic hazard

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Imipenem / Cilastatin / Relebactam Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.5	14.04.2025	68822-00033	Date of first issue: 27.02.2015

Eye Irrit.	:	Eye irritation
Repr.	:	Reproductive toxicity
Resp. Sens.	:	Respiratory sensitisation
STOT RE	:	Specific target organ toxicity - repeated exposure
IE OEL	:	Ireland. List of Chemical Agents and Carcinogens with Occu- pational Exposure Limit Values - Code of Practice, Schedule 1 and 2
IE OEL / OELV - 8 hrs (TWA)	:	Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Eye Irrit. 2	H319
Resp. Sens. 1	H334

Classification procedure:

Calculation method
Calculation method

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Imipenem / Cilastatin / Relebactam Formula- tion

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
5.5	14.04.2025	68822-00033	Date of first issue: 27.02.2015

Repr. 2	H361d	Calculation method
STOT RE 2	H373	Calculation method
Aquatic Acute 1	H400	Calculation method
Aquatic Chronic 1	H410	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN